News
Automatically gathered and summarized from longevity-focused publications, with links to the original reporting.
lifespan.io · Oct 23, 2026
Laura Minquini on the Quest for Female LongevityLaura Minquini is not a scientist, but that hasn’t stopped her from joining the front lines of the war on aging: specifically, female reproductive aging. Several years ago, after a successful stint in consumer technology, Laura discovered the longevity field when decentralized science was all the rage.
Read original →longevity.technology · Oct 23, 2026
Beyond Alzheimer’s: Quantum AI hunts new uses for XProINmune Bio is pairing a quantum machine with AI to find diseases beyond Alzheimer’s that its drug candidate might help. Drug developers usually pick a disease and go looking for a molecule to treat it. INmune Bio has flipped that around.
Read original →longevity.technology · Oct 23, 2026
Alaunos buys Velaris, raises $350m for lung drugsThe Florida biotech takes on a pulmonary hypertension pipeline backed by Fairmount, with cash it says should last into 2029. Alaunos Therapeutics , based in Fort Lauderdale, has an obesity program at the center of how it describes itself. That program is ALN1003, an oral small molecule the company calls a non-hormonal, non-incretin approach.
Read original →longevity.technology · Oct 23, 2026
Immorta Bio’s nine-amino-acid peptide aims at zombie cellsImmorta Bio says its AI-designed SenoMune-0257 prompts T cells to clear senescent cells, and plans first human evaluation before year-end. The molecule at the center of Immorta Bio ’s latest announcement is just nine amino acids long, which is tiny by drug standards.
Read original →longevity.technology · Oct 23, 2026
Big Pharma, clocks and clinics converge at 7th TimePie ForumTimePie’s Hebe Chen spotlights key developments from Shanghai, from therapeutic targets to China’s expanding clinical longevity footprint. A biological clock that measures the pace of aging, a drug being tested for age-related conditions, a biotech company developing new therapies, and a clinic offering longevity-focused care.
Read original →longevity.technology · Oct 23, 2026
L-Nutra Health launches metabolic programme to UK clinics - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: L-Nutra Health has launched a clinician-led metabolic health programme in the United Kingdom, making it available to clinics and medical practices for the first time.
Read original →longevity.technology · Oct 23, 2026
NRG Therapeutics launches brain-tracking study for new neurodegenerative drug - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 23, 2026
Muna Therapeutics' Alzheimer's drug MNA-001 passes early safety trial - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: Muna Therapeutics announced positive Phase 1 results for MNA-001, an oral small-molecule modulator of TREM2.
Read original →longevity.technology · Oct 23, 2026
FDA clears NeuroXT’s AI software to assess Alzheimer’s progression risk - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 23, 2026
Mind the gap: pregnancy, recovery and the aging clockA new review argues postpartum recovery may shape lifelong aging; a fandom health standard asks who helps mothers get there. Pregnancy ages a woman – measurably, if not necessarily permanently. The more interesting question, according to a new review in Trends in Endocrinology & Metabolism , is what happens afterwards.
Read original →longevity.technology · Oct 23, 2026
Amylin drug cuts weight up to 9.2% in diabetes trialZealand Pharma’s petrelintide delivered up to 9.2% weight loss over 28 weeks in people with obesity and type 2 diabetes, with few dropouts. Here is the figure that jumped out first. Just 1.9% of people taking petrelintide in a new Phase 2 trial stopped because of stomach-related side effects. In the placebo group, it was 1.7%. That is a very small gap.
Read original →lifespan.io · Oct 22, 2026
How Some Neuronal Cilia May Affect the Whole BodyA team of researchers has written a paper with a surprising finding: that many of the benefits of caloric restriction and increased NAD+ may be due to their effects on the cilia of hypothalamic neurons .
Read original →longevity.technology · Oct 22, 2026
Niagen expands at-home injection kit with new liquid formatNiagen Bioscience’s new Niagen Plus vial comes pre-filled and needs no mixing. It is available via a telehealth platform from 22 October. The pitch for Niagen Bioscience ’s latest product starts with what has been taken out of the process. Older injectable formats need mixing or reconstitution before use.
Read original →longevity.technology · Oct 22, 2026
Lewy body drug candidate gets patent cover to 2045Cognition Therapeutics wins a US patent on a new crystal form of zervimesine and has an FDA meeting on its Lewy body trial lined up. Cognition Therapeutics announced that its lead drug candidate, zervimesine (CT1812), now has patent protection running to 2045. The US Patent and Trademark Office granted a patent on a novel crystalline form of the drug, known as a polymorph. It’s US Patent No.
Read original →longevity.technology · Oct 22, 2026
Zealand taps Generate’s AI for obesity proteins in nearly $1.2b dealZealand Pharma and Generate Biomedicines will design multispecific proteins for metabolic disease, in a deal with nearly $1.2b in milestones. Zealand Pharma has been a peptide company for more than 25 years, and now the Copenhagen outfit is asking an AI specialist to help it branch into proteins. The announcement came on 13 October.
Read original →longevity.technology · Oct 22, 2026
NeuroXT earns FDA clearance for AI brain scan analyzer for Alzheimer's - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 22, 2026
Fountain Life named Longevity Clinic of the Year - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: Fountain Life has been named Longevity Clinic of the Year 2026 by the Roundtable of Longevity Clinics, marking its second consecutive year receiving the award.
Read original →longevity.technology · Oct 22, 2026
Eos SENOLYTIX invites the public to keep pace with SpeedyAs its CEO takes the stage in Berlin, the company opens a window on its longest-lived treated mice – and the data behind them. Most laboratory mice live and die in obscurity. Speedy has a webpage .
Read original →longevity.technology · Oct 22, 2026
Eos puts new gerotherapeutic to the test in aging miceBerlin keynote details Eos SENOLYTIX’s pre-clinical results with mitochondrial-targeted geropeptide on healthspan and lifespan. A 167-week-old mouse makes an unlikely but persuasive ambassador for geroscience, particularly when he appears to be moving around with considerably more energy than animals more than a year his junior.
Read original →longevity.technology · Oct 21, 2026
Roche licenses Rona’s RNAi drug that targets fat cellsRona Therapeutics grants Roche worldwide rights to an ALK7-silencing candidate, with up to $1.06b in further milestones on the table. Visceral fat is the deep kind, the stuff that wraps around organs in the abdomen, and a small RNA company in Santa Barbara has just handed Roche the rights to a drug that goes after it. Rona Therapeutics announced the exclusive worldwide license on 13 October.
Read original →longevity.technology · Oct 21, 2026
Insilico’s AI-built pill cuts colitis scores by 60% in animal testsInsilico Medicine nominates ISM9546, an oral VAV1 degrader designed with generative AI, as a preclinical candidate for autoimmune disease. Some proteins have a reputation for being impossible to hit with a drug. VAV1 is one of them, and Insilico Medicine says an AI-designed pill has now taken a decent swing at it. The Hong Kong-listed company nominated ISM9546 as a preclinical candidate.
Read original →longevity.technology · Oct 21, 2026
Shift fixes how AI ‘virtual cells’ get gradedNature Biotechnology paper offers a better way to judge models that predict gene effects. Shift plans to use it to hunt for aging targets. Picture a weather forecaster who keeps getting marked wrong, and then someone realizes the scoring sheet was the problem. That’s roughly the story Shift Bioscience is telling about AI “virtual cells,” and it has a Nature Biotechnology paper to back it up.
Read original →longevity.technology · Oct 21, 2026
Blood sensor hunts Parkinson’s signals in 40 minutesKAUST and Oxford researchers used a transistor-based sensor to read three forms of alpha-synuclein, reaching 90.9% accuracy in a small study. Blood is a messy place to go looking for brain clues. More than 95% of the alpha-synuclein floating around in it comes from red blood cells, and the small share that might say something about Parkinson’s disease gets buried underneath.
Read original →longevity.technology · Oct 21, 2026
Measure, treat, repeat: the push to standardize longevity medicineFourth Roundtable of Longevity Clinics sees clinic leaders tackle the ‘luxury diagnostic’ trap and the push for standardized care. At this weekend’s Roundtable of Longevity Clinics, organized by the International Institute of Longevity and chaired by Buck Institute CEO Eric Verdin MD, leading clinic founders agreed that the longevity sector has reached an inflection point.
Read original →longevity.technology · Oct 21, 2026
Omada Health to present research on weight loss during GLP-1 therapy - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
Read original →longevity.technology · Oct 21, 2026
Rivus to present data on new oral weight-loss drug that targets fat while saving muscle - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 21, 2026
FDA clears Phase 2 trial for United Therapeutics' COPD lung disease treatment - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: The U.S.
Read original →longevity.technology · Oct 21, 2026
Insilico reaches first milestone in Servier collaboration - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →lifespan.io · Oct 20, 2026
AI Extracts Broader Health Insights From Routine CT ScansA new study suggests that CT scans can provide information about a wide range of conditions , including some not typically diagnosed through imaging. Direct comparison with human radiologists is the next step [1]. Getting more from a scan A CT scan’s goal is usually to answer a concrete clinical question, such as what is causing abdominal pain or whether a suspected tumor is there.
Read original →longevity.technology · Oct 20, 2026
Alterity reanalysis puts MSA drug at 52% slowingAdjusting for how advanced patients’ disease was at the start lifts the Phase 2 result. The method was added after the trial began. Alterity Therapeutics has a number it would like you to remember, and the number is 52. That’s the percentage by which its experimental drug ATH434 slowed functional decline in multiple system atrophy (MSA), according to a fresh look at its Phase 2 data [ 1 ].
Read original →longevity.technology · Oct 20, 2026
Parkinson’s test-and-drug duo wins CPHI awardGerman biotech MODAG won for pairing a CE-marked diagnostic with a drug candidate that targets the same protein. The jury at CPHI Milan had a pattern to break. For three years running, the API Development and Innovation award had gone to manufacturers with new production processes.
Read original →longevity.technology · Oct 20, 2026
Veradermics to discuss Phase 3 '304' topline results on call - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
Read original →longevity.technology · Oct 20, 2026
XellSmart reports Phase I Parkinson's cell therapy data - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: New clinical data for XellSmart’s off-the-shelf cell therapy XS411 were presented at the International Congress of Parkinson’s Disease and Movement Disorders on 18 Oct. 2026.
Read original →lifespan.io · Oct 19, 2026
An RNA Regulator Mitigates Senescence in Blood VesselsResearchers publishing in Aging Cell have found that the regulatory protein MTR4 fights DNA damage in the blood vessel lining but decreases with aging . Vulnerable by nature This paper begins by noting the properties, and aging, of vascular endothelial cells (VECs), which line the blood vessels and govern their permeability [1].
Read original →longevity.technology · Oct 19, 2026
Sub-$60 DEXA body scans open in OaklandBodySpec’s new storefront targets muscle loss from GLP-1 weight loss drugs, with scans said to take about 12 minutes. Your bathroom scale is a bit of a liar by omission. It’ll tell you that you’ve lost eight pounds and keep quiet about whether those pounds were fat, muscle or something else.
Read original →longevity.technology · Oct 19, 2026
VectorY triples ALS trial before efficacy dataVectorY is growing PIONEER-ALS from 12 to 36 participants to test VTx-002, an antibody therapy aimed at the protein TDP-43. VectorY Therapeutics has just tripled the size of its ALS trial, and it did so before seeing any efficacy data. The Phase 1/2 PIONEER-ALS study of VTx-002 will now enroll 36 people instead of 12 [ 1 ]. That order of events is the interesting part.
Read original →longevity.technology · Oct 19, 2026
29% of long-term GLP-1 users lack nutrient confidenceA Censuswide survey commissioned by PortionIQ finds confidence is lower among longer-term users, though it’s a snapshot from one brand. Everybody seems to be Googling GLP-1 lately. Searches for the term ran 120% higher over the past year than the year before, according to Google Trends data cited in a new UK report.
Read original →longevity.technology · Oct 19, 2026
Resveratrol Parkinson’s trial doses first patientJupiter Neurosciences also hired an adviser to explore a sale or licensing of its assets while the 30-person trial gets underway. Two pieces of news arrived in one press release from Jupiter Neurosciences earlier this month, and they pull in somewhat different directions. The Florida company dosed the first patient in a Phase 2a Parkinson’s trial.
Read original →longevity.technology · Oct 19, 2026
Amprion and Prema link memory tests to biomarkersA quick digital memory test and a lab assay for brain disease are teaming up to flag neurodegeneration earlier. Walk into a kitchen, forget why you’re there, laugh it off. Most of us have done it. But some people notice their memory slipping in ways that feel different, then sit a standard cognitive screening and score perfectly normal.
Read original →longevity.technology · Oct 19, 2026
Intrinsic capacity: A new way to measure healthy agingForget the diagnosis count. The researcher who helped the WHO reframe aging says function, not disease, is the better yardstick. Ask most health systems how healthy you are, and they start counting: diagnoses, prescriptions, conditions on a chart. It is a ledger of what has gone wrong, and for decades it has passed for a measure of health. Dr John Beard spent ten years trying to flip that ledger.
Read original →longevity.technology · Oct 19, 2026
Mission Therapeutics doses first Parkinson’s patient in Phase 1b - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 19, 2026
Oxford Healthspan introduces mixable spermidine supplement - Longevity.TechnologyLongevity.Technology is a registered trademark of First Longevity Limited. First Longevity Ltd. Registered Office: 2 Communications Road, Greenham Business Park, Newbury, Berkshire, RG19 6AB. Registered in England No.: 12345643 First Logevity Limited provides a service to strictly match groups or individuals seeking investment capital with individuals looking to invest.
Read original →longevity.technology · Oct 19, 2026
Elysium launches Balance for perimenopause, menopause support - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: Elysium has launched Balance, a supplement aimed at perimenopause and menopause that combines Basis with S-equol and ergothioneine to target disruptive symptoms and longer-term health.
Read original →longevity.technology · Oct 19, 2026
Fractyl Revita reduces post-GLP-1 weight regain in pivotal study - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.
Read original →longevity.technology · Oct 19, 2026
Renue by Science launches home-based health research community - Longevity.TechnologyLongevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision. Please get in touch if you are interested: Renue by Science has launched the Renue Research Community, a platform that allows consumers to take part in structured, Institutional Review Board-reviewed research from home.
Read original →fightaging.org · Oct 17, 2026
Fight Aging! Newsletter, October 19th 2026Fight Aging! publishes news and commentary relevant to the goal of ending all age-related disease, to be achieved by bringing the mechanisms of aging under the control of modern medicine. This weekly newsletter is sent to thousands of interested subscribers. To subscribe to the newsletter, please visit: https://www.fightaging.org/newsletter/ .
Read original →fightaging.org · Oct 17, 2026
A Micropeptide that Inhibits Vascular Calcification via PKM2 DegradationThe vascular system is prone to calcification with advancing age. Cells in the vasculature inappropriately take on the features and behavior of the osteoblast cells responsible for building bone extracellular matrix . These errant vascular cells deposit calcium phosphate structures into vascular tissue, stiffening it.
Read original →lifespan.io · Oct 16, 2026
Blocking STING Helps Preserve Bone in Aging MiceA new study links STING-mediated signals from marrow fat cells to inflammation and declining NAD⁺ levels in bone-forming cells. Interrupting this pathway helped preserve aging bone [1]. Making old bones Our bones live a complex life, as they are constantly remodeled: cells called osteoclasts break down existing bone, while osteoblasts build new bone.
Read original →longevity.technology · Oct 16, 2026
Longeveron’s stem cell data hint at calmer brainsA new preprint links the company’s cell therapy to less brain inflammation in Alzheimer’s, just as it heads out on an investor tour. Longeveron went back to its Alzheimer’s data and took a second look. The Miami company’s CLEAR MIND trial, a Phase 2a study of 49 people, already reported its main results in Nature Medicine in 2025.
Read original →longevity.technology · Oct 16, 2026
Prenuvo opens its 200K MRI scans to researchersThe whole-body scan company is launching a research network with 50+ institutions. Early findings come with some big open questions. Seven in every 100 people. That’s how many showed a clinically significant brain abnormality in a Prenuvo study of more than 78,000 people who chose a preventive whole-body MRI.
Read original →